RxDoctor Payments Data

Agatha Chukwumerije, MD

Internal Medicine · Canton, OHNPI 1093820508

Payments from drug & device makers

$3,151in general payments, 2019–2025

Across 136 payments — averaging $23.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Medtronic$612
  • Pfizer$238
  • AbbVie$154
  • Lilly USA, LLC$126
  • Amarin Pharma, Inc.$95
  • plus $337 from 9 others

What the payments were for

  • Travel & lodging$46215%
  • Food & beverage$2,68885%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,151 in reported general payments places this provider in the 85th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$22,744
Medicare patients
52
Services billed
263

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol81$63,278
TrulicityDulaglutide34$53,220
OzempicSemaglutide25$36,356
XareltoRivaroxaban31$22,891
EliquisApixaban22$13,547
JanuviaSitagliptin Phosphate17$13,410
JardianceEmpagliflozin14$12,933
SymbicortBudesonide/Formoterol Fumarate34$12,751
Lantus SolostarInsulin Glargine,hum.Rec.Anlog61$7,913
Breo ElliptaFluticasone/Vilanterol12$5,005
Venlafaxine Hcl ErVenlafaxine Hcl12$4,388
Albuterol Sulfate HfaAlbuterol Sulfate150$3,725
Fluticasone Propionate182$2,924
Atorvastatin Calcium296$2,062
Metformin Hcl259$1,843

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$1,588$76,029115 claims
Lilly USA, LLCTrulicity$126$53,22034 claims
Novo NordiskOzempic$72$36,35625 claims
PfizerEliquis$238$13,54722 claims
MerckJanuvia$15$13,41017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Canton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →